Stevanato Group S.p.A. (STVN)
| Previous Close | 20.32 |
| Open | 20.36 |
| Bid | 20.30 x 800 |
| Ask | 20.41 x 800 |
| Day's Range | 20.17 - 20.90 |
| 52 Week Range | 18.85 - 36.30 |
| Volume | |
| Avg. Volume | 596,909 |
| Market Cap | 5.521B |
| Beta (5Y Monthly) | 0.76 |
| PE Ratio (TTM) | 36.80 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.06 (0.30%) |
| Ex-Dividend Date | Jun 07, 2023 |
| 1y Target Est | N/A |
- Business Wire
Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill® Syringes and Cartridges
PIOMBINO DESE, Italy, May 30, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant.
- Business Wire
Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro
PIOMBINO DESE, Italy, May 28, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that its Board of Directors has appointed Franco Stevanato, a current director and the Executive Chairman of the Company, as its new Chief Executive Officer. Mr. Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will
- Business Wire
Stevanato Group Announces Results of Annual General Meeting
PIOMBINO DESE, Italy, May 24, 2024--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed.
